Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.

Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Sept 2007Cited by 116 (Europe PMC)

PMID17872344DOI10.4158/ep.13.5.444PepBankPUB-17872344

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In obese adults with diabetes, regular exenatide use was linked to decreased weight from baseline, while weight increased in patients who discontinued exenatide.
In plain wordsRegular exenatide use was linked to lower weight than baseline, while weight rose in patients who stopped exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight
Study
n = 38
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mcg twice daily · Mean 26 weeksAs given in this study (human).
Measurements
Weight decrease
6.46 kg
regular use group (Group A)
Weight increase
2.4 kg
Group B, discontinued exenatide
Source sentences
Summary
Mean body weight (+/- standard error of the mean) decreased by 6.46 +/- 0.8 kg (P<.001) in Group A and increased by 2.4 +/- 0.6 kg in Group B (P<001).
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective analysis, clinical progress of 52 obese patients with type 2 diabetes treated with exenatide, 5 mcg twice daily, in an outpatient setting was reviewed.
Summary · context
Mean follow-up period was 26 weeks.
Summary · context
Thirty-eight patients took exenatide regularly (Group A); 14 patients discontinued exenatide because of insurance, personal, or economic reasons (Group B).
Report a problemFND-1787234401
02HumanObservational studyEfficacy outcome
In obese adults with diabetes, regular exenatide use was linked to lower HbA1c than baseline.
In plain wordsRegular exenatide use was linked to lower blood sugar than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 38
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mcg twice daily · Mean 26 weeksAs given in this study (human).
Measurements
HbA1c decrease
0.6%
regular use group
Source sentences
Summary
In Group A, mean HbA1c decreased by 0.6 +/- 0.21% (P = .007), and the insulin dosage requirement decreased for rapid-acting and mixed insulins (P<.02).
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective analysis, clinical progress of 52 obese patients with type 2 diabetes treated with exenatide, 5 mcg twice daily, in an outpatient setting was reviewed.
Summary · context
Mean follow-up period was 26 weeks.
Summary · context
Thirty-eight patients took exenatide regularly (Group A); 14 patients discontinued exenatide because of insurance, personal, or economic reasons (Group B).
Report a problemFND-1787234402
03HumanObservational studyEfficacy outcome
In obese adults with diabetes, regular exenatide use was linked to reduced total cholesterol from baseline.
In plain wordsRegular exenatide use was linked to lower total cholesterol than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal cholesterol
Study
n = 38
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
5 mcg twice daily · Mean 26 weeksAs given in this study (human).
Measurements
Total cholesterol decrease
8.5%
regular use group
Source sentences
Summary
In Group A, means of the following parameters decreased: serum total cholesterol by 8.5 +/- 3.3% (P = .03)
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective analysis, clinical progress of 52 obese patients with type 2 diabetes treated with exenatide, 5 mcg twice daily, in an outpatient setting was reviewed.
Summary · context
Mean follow-up period was 26 weeks.
Summary · context
Thirty-eight patients took exenatide regularly (Group A); 14 patients discontinued exenatide because of insurance, personal, or economic reasons (Group B).
Report a problemFND-1787234405
04HumanObservational studyEfficacy outcome
In obese adults with diabetes, regular exenatide use was linked to reduced triglycerides from baseline.
In plain wordsRegular exenatide use was linked to lower triglycerides than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTriglycerides
Study
n = 38
Comparator
Baseline
Outcome group
Lipids · Metabolic and weight
Studied dose
5 mcg twice daily · Mean 26 weeksAs given in this study (human).
Measurements
Triglyceride decrease
26%
regular use group
Source sentences
Summary
triglycerides by 26 +/- 7.6% (P = .01)
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective analysis, clinical progress of 52 obese patients with type 2 diabetes treated with exenatide, 5 mcg twice daily, in an outpatient setting was reviewed.
Summary · context
Mean follow-up period was 26 weeks.
Summary · context
Thirty-eight patients took exenatide regularly (Group A); 14 patients discontinued exenatide because of insurance, personal, or economic reasons (Group B).
Report a problemFND-1787234406
05HumanObservational studyEfficacy outcome
In obese adults with diabetes, regular exenatide use was linked to reduced systolic blood pressure from baseline.
In plain wordsRegular exenatide use was linked to lower systolic blood pressure than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure
Study
n = 38
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
5 mcg twice daily · Mean 26 weeksAs given in this study (human).
Measurements
Systolic pressure decrease
9.2 mm Hg
regular use group
Source sentences
Summary
systolic blood pressure by 9.2 +/- 3.3 mm Hg (P = .02)
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective analysis, clinical progress of 52 obese patients with type 2 diabetes treated with exenatide, 5 mcg twice daily, in an outpatient setting was reviewed.
Summary · context
Mean follow-up period was 26 weeks.
Summary · context
Thirty-eight patients took exenatide regularly (Group A); 14 patients discontinued exenatide because of insurance, personal, or economic reasons (Group B).
Report a problemFND-1787234407
06HumanObservational studyEfficacy outcome
In obese adults with diabetes, regular exenatide use was linked to reduced high-sensitivity CRP from baseline.
In plain wordsRegular exenatide use was linked to lower inflammation marker CRP than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHigh-sensitivity CRP
Study
n = 38
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 mcg twice daily · Mean 26 weeksAs given in this study (human).
Measurements
CRP decrease
34%
regular use group
Source sentences
Summary
and high-sensitivity CRP by 34 +/- 14.3% (P = .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective analysis, clinical progress of 52 obese patients with type 2 diabetes treated with exenatide, 5 mcg twice daily, in an outpatient setting was reviewed.
Summary · context
Mean follow-up period was 26 weeks.
Summary · context
Thirty-eight patients took exenatide regularly (Group A); 14 patients discontinued exenatide because of insurance, personal, or economic reasons (Group B).
Report a problemFND-1787234408
07HumanObservational studyEfficacy outcome
In obese adults with diabetes, regular exenatide use was linked to reduced rapid-acting insulin requirements.
In plain wordsRegular exenatide use was linked to lower rapid-acting insulin needs than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseRapid-acting insulin requirement
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mcg twice daily · Mean 26 weeksAs given in this study (human).
Source sentences
Summary
In Group A, mean HbA1c decreased by 0.6 +/- 0.21% (P = .007), and the insulin dosage requirement decreased for rapid-acting and mixed insulins (P<.02).
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective analysis, clinical progress of 52 obese patients with type 2 diabetes treated with exenatide, 5 mcg twice daily, in an outpatient setting was reviewed.
Summary · context
Mean follow-up period was 26 weeks.
Summary · context
Thirty-eight patients took exenatide regularly (Group A); 14 patients discontinued exenatide because of insurance, personal, or economic reasons (Group B).
Report a problemFND-1787234403
08HumanObservational studyEfficacy outcome
In obese adults with diabetes, regular exenatide use was linked to reduced mixed insulin requirements.
In plain wordsRegular exenatide use was linked to lower mixed insulin needs than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMixed insulin requirement
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mcg twice daily · Mean 26 weeksAs given in this study (human).
Source sentences
Summary
In Group A, mean HbA1c decreased by 0.6 +/- 0.21% (P = .007), and the insulin dosage requirement decreased for rapid-acting and mixed insulins (P<.02).
3 context sentences(design, population, supporting numbers)
Summary · context
In this retrospective analysis, clinical progress of 52 obese patients with type 2 diabetes treated with exenatide, 5 mcg twice daily, in an outpatient setting was reviewed.
Summary · context
Mean follow-up period was 26 weeks.
Summary · context
Thirty-eight patients took exenatide regularly (Group A); 14 patients discontinued exenatide because of insurance, personal, or economic reasons (Group B).
Report a problemFND-1787234404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.